Edward E Beedle is a prominent inventor based in Indianapolis, IN (US). He has made significant contributions to the field of pharmacology, particularly in the development of selective antagonists for the 5-HT.sub.1A receptor. With a total of 8 patents to his name, Beedle's work has had a considerable impact on medicinal chemistry.

Latest Patents

Among his latest patents, Beedle has developed methods involving the use of propanolamine derivatives as selective 5-HT.sub.1 antagonists. This invention provides a method of selectively antagonizing the 5-HT.sub.1A receptor in mammals by administering aryloxypropanolamines. Additionally, he has patented cycloalkylaminoalkoxyindoles, which also focus on selectively antagonizing the 5-HT.sub.1A receptor through similar means.

Career Highlights

Edward E Beedle is currently associated with Eli Lilly and Company, a leading pharmaceutical firm known for its innovative research and development. His work at Eli Lilly has allowed him to explore new avenues in drug development and contribute to advancements in therapeutic options.

Collaborations

Throughout his career, Beedle has collaborated with notable colleagues, including David W Robertson and David T Wong. These partnerships have fostered a collaborative environment that enhances the innovation process.

Conclusion

Edward E Beedle's contributions to the field of pharmacology through his patents and collaborations highlight his role as a significant inventor. His work continues to influence the development of new therapeutic agents, showcasing the importance of innovation in medicine.